Table 1 |
|
|
Registered and potential indications of recombinant activated factor VII in patients undergoing abdominal surgery |
|
| Registered indications |
Prophylaxis of bleeding related to surgical or invasive interventions as well as treatment
of bleeding in patients with |
| -Congenital hemophilia A or B if inhibitors are present (>5 Bethesda units) or if
a strong increase of inhibitors must be expected upon administration of factor VIII
or IX [41] |
|
| - Acquired hemophilia [42] |
|
| - Congenital factor VII deficiency [43] |
|
| - Glanzmann thrombasthenia with antibodies to glycoprotein IIb/IIIa and/or human leucocyte
antigen and presence or history of refractoriness to platelet concentrates [44] |
|
|
|
|
| Potential indications |
Prophylaxis of surgical bleeding in patients with reduced activity or deficiency of
coagulation factors, especially with specific inhibitors to plasmatic factors [45]
and acquired von Willebrand disease [46] |
| Treatment of bleedings after all conventional measures have failed in patients with |
|
| - Chronic liver disease [47] |
|
| - Thrombocytopathy [48] |
|
| - Platelet-refractory thrombopenia [49] |
|
| - Bleeding complications due to trauma or surgery in patients without any detectable
systemic impairment of hemostasis (references in Tables 3 and 4) |
|
| - Drug-induced bleeding, especially by hirudine (in connection with supportive measures),
danaparoid, fondaparinux, and glycoprotein IIb/IIIa inhibitors [50] |
|
|
|
|
|
von Heymann et al. Critical Care 2008 12:R14 doi:10.1186/cc6788 |
|
